189 related articles for article (PubMed ID: 24671840)
1. [Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting].
Granata A; Insalaco M; Di Nicolò P; Scarfia VR; Russo L; D'anna G; Lentini P; Fiorini F; Fatuzzo P
G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671840
[TBL] [Abstract][Full Text] [Related]
2. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease.
Reilly JB; Berns JS
Semin Dial; 2010; 23(2):163-8. PubMed ID: 20210915
[TBL] [Abstract][Full Text] [Related]
3. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
Game F
Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
[TBL] [Abstract][Full Text] [Related]
4. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.
Snyder RW; Berns JS
Semin Dial; 2004; 17(5):365-70. PubMed ID: 15461745
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
[TBL] [Abstract][Full Text] [Related]
6. [Use of oral hypoglycemic agents in patients with chronic kidney failure].
Libardi F; Sirolli V; Cappelli P; Bonomini M
G Ital Nefrol; 2009; 26(6):679-85. PubMed ID: 19918750
[TBL] [Abstract][Full Text] [Related]
7. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Charbonnel B; Schweizer A; Dejager S
Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
[TBL] [Abstract][Full Text] [Related]
9. Oral antidiabetic agents in type 2 diabetes.
Levetan C
Curr Med Res Opin; 2007 Apr; 23(4):945-52. PubMed ID: 17407651
[TBL] [Abstract][Full Text] [Related]
10. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
Abe M; Okada K
Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019
[TBL] [Abstract][Full Text] [Related]
11. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents.
Di Lullo L; Mangano M; Ronco C; Barbera V; De Pascalis A; Bellasi A; Russo D; Di Iorio B; Cozzolino M
Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S295-S305. PubMed ID: 28292575
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic indications of incretin-related derivatives and other oral hypoglycemic agents].
Katsuno T; Miyagawa J
Nihon Rinsho; 2012 May; 70 Suppl 3():693-8. PubMed ID: 22768600
[No Abstract] [Full Text] [Related]
13. [New oral hypoglycemic drugs in diabetic kidney disease].
Dylewska M; Graczyk M
Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
[TBL] [Abstract][Full Text] [Related]
14. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
Dejager S; Schweizer A
Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
[TBL] [Abstract][Full Text] [Related]
15. [Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes].
Jojima T; Aso Y
Nihon Rinsho; 2013 Nov; 71(11):1987-92. PubMed ID: 24397171
[TBL] [Abstract][Full Text] [Related]
16. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
18. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
19. [Antidiabetic agents and renal insufficiency].
Robles NR; Blanco J
Nefrologia; 2002; 22(4):325-8. PubMed ID: 12369123
[No Abstract] [Full Text] [Related]
20. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
Fisman EZ; Tenenbaum A; Motro M; Adler Y
Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
